ECFS 2020 - Optimizing pharmaceutical care in cystic fibrosis

274 OPTIMIZING PHARMACEUTICAL CARE IN CYSTIC FIBROSIS ECFS-CTN: SHAPING SMALL GAINS INTO MAGIC BULLETS CHAPTER 15 [13] Amaral MD, de Boeck K. Theranos- tics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations. J Cyst Fibros. 2019;18(5):685-92. [14] Schroll JB, Penninga EI, Gotzsche PC. Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis. PLoS medicine. 2016;13(8):e1002101.